No­var­tis heads to the fin­ish line with CDK 4/6 block­buster con­tender ri­bo­ci­clib

In the fi­nal stretch in its jour­ney to reg­u­la­tors, No­var­tis post­ed a pos­i­tive snap­shot of piv­otal Phase III da­ta on its CDK 4/6 con­tender ri­bo­ci­clib (LEE011), set­ting up a like­ly show­down with Pfiz­er in treat­ing breast can­cer.

The head­line fig­ure from ES­MO is that ri­bo­ci­clib com­bined with letro­zole re­duced the risk of death or pro­gres­sion by 44% among first-line pa­tients com­pared to letro­zole alone, of­fer­ing fur­ther en­cour­age­ment to the phar­ma gi­ant that it’s right on track to gain­ing an ap­proval for this drug next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA